Peggy Knight Named Executive Vice President and Chief Marketing Officer of Type2Defense(tm) Diabetes Product

Follow this company

Companies Mentioned

08/05/2014 [ACCESSWIRE]

Peggy Knight Named Executive Vice President and Chief Marketing Officer of Type2Defense(tm) Diabetes Product

SAN ANTONIO, TX / ACCESSWIRE / Aug 5, 2014 / Peggy Knight has been named Executive Vice President and Chief Marketing Officer of “Type2 Defense(tm),” a product owned by Bio-Solutions Corporation (OTCQB:BISU).

“We are delighted to have someone with Ms. Knight’s retail background involved with Type2Defense(tm). We will lean heavily on Ms. Knight’s experience as we develop the market for our product,” said Chairman of the Board and interim CEO James Hodge. “Ms. Knight had a long, illustrious career with Wal-Mart and Sam’s Club, and we look forward to utilizing her knowledge for our Type2Defense(tm) product.”

Ms. Knight commented, “I am happy to join Bio-Solutions Corporation. Type2Defense(tm) has exciting benefits for a large percentage of the population, and we look forward to selling this revolutionary product at retail level.”

Type2 Defense(tm) was developed by Dr. Chandraskehar Mallangi, a former Nestle’ USA nutritional Innovator and Developer of multiple Nestle’ USA Product lines. The product is a nutritional supplement delivered as a soluble that targets health conscious individuals diagnosed as Type II diabetics, as well as individuals taking a proactive approach to pre-diabetic symptoms. The Type2 Defense(tm) powder blend is a safe and all-natural supplement that can aid the stabilization of healthy glucose levels and healthy blood pressure through a compound that includes strong antioxidants. The mix contains green tea, cinnamon and blueberry flavors, and the Type2 Defense(tm) proprietary blend.

About Bio-Solutions Corp.

Bio-Solutions Corp (OTCQB:BISU), Owns and Markets Type2 Defense(TM), a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure. The company believes that there is a growing Diabetic target market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense is a powder blend of natural ingredients that has been developed to maintain healthy blood glucose levels. For more information, visit, or

NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management 's views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management "believes", "expects", "anticipates", "foresees", "forecasts", "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that the ability to attract clients and generate business may be affected by a decline in the Company's financial ratings, the competitive environment, the Company's ability to raise sufficient capital to meet the collateral requirements associated with its current business and to fund the Company's continuing operations and changes in market conditions.


Kelly Coughlin
Annex Communication
(954) 332.3688 o.
(954) 294.9135 c.


Source: Bio-Solutions Corporation


Leave a comment...

Your Name